Fighting COVID-19 With a Menu That Matters

Learn more about four different tests that are changing the landscape in the fight against COVID-19.
Fighting COVID-19 With a Menu That Matters

Patients and healthcare professionals alike are striving to gain clarity when it comes to COVID-19 infection status. What is the best way to achieve that? Reliable, affordable and frequent testing.

As cases continue to soar, masks, social distancing and frequent testing are our best defense against COVID-19. To support you in the fight against the pandemic, Beckman Coulter has spent countless hours developing a "menu that matters".

 

Figure 1: A menu that matters in the fight against COVID-19. Graphic developed with supporting evidence from Nature Editorial (2020).1

COVID-19 Antibody Assays

Serology assays detect antibodies in response to the SARS-CoV-2 virus, indicating whether a patient has potentially had a recent or prior COVID-19 infection. Broadly used serology assays are essential in the fight against COVID-19, as they provide an understanding of how many people have developed antibodies, and how far the pandemic has progressed.

IgM antibodies, in general, are the body’s first line of defense against a virus and can be detected approximately four to seven days after someone has been infected. With Beckman Coulter’s Access SARS-COV-2 IgM test, a laboratory can learn information about an individual’s immune response with a high sensitivity (100%) and specificity (99.9%).*

IgG antibodies, in general offer a more sustained immune response to a virus. Beckman Coulter’s Access SARS-COV-2 IgG antibody test features market-leading sensitivity (100%) and specificity (99.6%).

With IgM and IgG assays, laboratories get a clear view of a patient’s antibody response. Both assays can be used in Random Access Mode (RAM), which means that the antibody tests can be run along with other immunoassay tests and can be used with Beckman Coulter analyzers in small, mid-sized, and large labs.

A New Assay in the COVID-19 Toolbox

Beckman Coulter’s Access SARS-CoV-2 IgG II is a semi-quantitative assay that measures a patient’s relative level of antibodies in response to a previous SARS-CoV-2 infection. This assay allows clinicians to establish a baseline to evaluate an individual’s immune response to COVID-19 based on a numerical value and assess changes in that response over time.

The assay has a confirmed 98.9% sensitivity rate at >/= 15 days post symptom onset and 100% specificity rate. Like Beckman Coulter’s IgG and IgM assays, it runs on award-winning immunoassay analyzers, including the DxI-800 high-throughput analyzer, which can process up to 200 samples per hour.

A New Challenge

With cases spiking at unprecedented levels globally, laboratories of all sizes are adjusting to keep up with mass testing. While point of care (POC) antigen tests are ideal in some cases, they can be resource-intensive to scale to address a high volume of tests.2 Beckman Coulter’s Antigen Test is a scalable, cost-effective, high-quality solution. Priced affordable, Beckman Coulter’s Antigen Test can deliver 50, 100, or 200 tests per hour, with rapid results for patients in high-risk settings.

Driving the Path Forward to End the Coronavirus Pandemic

Beckman Coulter continues to add to a menu that matters, developing assays that focus on patient care and lab efficiency. These assays, along with Beckman Coulter’s immunoassay analyzers, optimize uptime, reliability, and performance.

For more information on all of the efforts to help fight COVID-19, visit www.beckmancoulter.com/coronavirus

References:

1Nature Editorial. (2020, September 16). Fast coronavirus tests: what they can and can’t do. Nature.https://www.nature.com/articles/d41586-020-02661-2?error=cookies_not_supported&code=1754f7f0-3735-47b7-9895-75e64ff7a635

2Varghese, P., Califf, R. M., Poole, S., Califf, R. M., Pendergrast, T., Jain, S., & Wilson, I. A. (2020, September 22). Fast, low-cost coronavirus testing can avert a new Covid-19 wave. STAT News. https://www.statnews.com/2020/09/23/fast-low-cost-coronavirus-testing-avert-new-wave-covid-19/

*Rate at >18 days post symptom onset

Note: Access SARS-CoV-2 IgG II and Access SARS-CoV-2 Antigen test has not been reviewed by the FDA. Testing is limited to laboratories certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA), 42 U.S.C. §263a, that meet the requirements to perform high complexity tests. Access SARS-CoV-2 IgG and are for Use Under the Emergency Use Authorization (EUA) Only. For In Vitro Diagnostic Use.

Editorial Team
Editorial Team
The Beckman Coulter editorial team brings you timely news and resources focused on elevating clinical laboratory performance and advancing patient care.

Related Articles

Automation for All

Automation for All

With solutions available for every sized lab, automation is now a necessity to optimize patient care.
Fully-Automated Urinalysis Launches at AACC

Fully-Automated Urinalysis Launches at AACC

Launch of the fully automated DxU Iris Workcell at the 2021 AACC Annual Scientific Meeting & Clinical Lab Expo
Avoiding Disruptions in Laboratory Workflow During Challenging Times

Avoiding Disruptions in Laboratory Workflow During Challenging Times

Today’s laboratories face many disruptions in workflow that delay patient care. Learn how automated urinalysis solutions can free-up time consuming bottlenecks.